ClinicalTrials.gg
RecruitingNCT06273657Updated Oct 28, 2026

Effects of Medisinstart for Type 2 Diabetes

An interventional study of Medisinstart in Type 2 Diabetes, sponsored by Apokus AS. Recruiting at 22 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Apokus AS · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Oct 28, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 116 studies in Diabetes Mellitus, Type 2 with a site in Norway — 3 open to participants now, 4 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Norway.

Planned enrollment
53rd of 103
500 · median 503
Started
2024
the only one that year
No phase
24 of 116
2 open now
Registered
113th of 116
by date

Among the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway, this one is the 53rd largest by planned enrollment of the 103 interventional ones that give a count, is the only one that started in 2024, is one of 24 with no phase, and was the 113th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Diabetes Mellitus, Type 2 with a site in Norway, or all of them as a file.
02

Study summary

Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up appointments with a pharmacist. The aim of the service is to promote correct medication use and increase patient adherence. The effect of Medisinstart has previously been studied among patients starting a new cardiovascular drug. The aim of the project is to map the effects of Medisinstart among patients starting a new medication for type 2 diabetes. Knowledge about the effects of Medisinstart is important in order to maximize the benefits of the service for patients and society. The project is being conducted as a randomized controlled trial among adult patients starting a new medication for type 2 diabetes. The intervention group receives Medisinstart, while the control group only receives prescription dispensing as normal. Data collection includes HbA1c analysis in blood samples and responses to questionnaires. HbA1c is an established measure of glycemic control.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Medication related problems
  • Adherence
  • Type 2 diabetes
  • Pharmacist-led intervention
  • Consultation
  • Pharmacy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Extracted a new drug/active substance (A10A/A10B) for type 2 diabetes
  • Age ≥ 18 years
  • The drugs are administered by the patient/relatives
  • Good command of Norwegian, both written and spoken

Exclusion criteria

Exclusion Criteria:

  • Inability to understand and/or complete consent forms, questionnaires and/or other patient-oriented materials
  • Not able to attend physical appointments in the pharmacy
  • Not given written consent to participate in the study
  • Diabetes medication is administered by a healthcare professional
  • Known pregnancy
  • is unsuitable as an average measure of blood glucose at baseline
  • Received initiation of medication for type 2 diabetes within the last year
  • Ongoing participation in other studies involving similar interventions to increase adherence and ensure correct medication use
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Medisinstart

    Other: Medisinstart

  • No intervention
    Control

Interventions

  • OtherMedisinstart

    Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.

06

What researchers measure

Primary outcomes

  1. HbA1c

    Change in HbA1c-level from baseline to 6 months after initiation of a new medication for type 2 diabetes.

    Time frame: At baseline and 6 months after initation of the new medication for type 2 diabetes.

  2. HbA1c

    Change in HbA1c-level from baseline to 12 months after initiation of a new medication for type 2 diabetes.

    Time frame: At baseline and 12 months after initation of the new medication for type 2 diabetes.

Secondary outcomes

  1. Self-reported adherence

    Adherence will be measured by a Norwegian translation of the MARS-5 questionnaire. The total MARS-5 score can have values from 5-25, with higher scores indicating higher adherence.

    Time frame: 6 and 12 months after initiation of the new medication for type 2 diabetes

  2. Self-reported adherence

    Adherence will be measured by a Norwegian translations of the question: "People often miss taking doses of their medicines, for a wide range of reasons. Have you missed any doses of your new medicine the last week?" The question will be answered by yes/no.

    Time frame: 6 and 12 months after initiation of the new medication for type 2 diabetes

  3. Frequency of medication-related problems

    Pharmacists will report identified medication-related problems (MRPs) in a structured self-developed electronic questionnaire. The MRP categories in the questionnaire are based on the MRP classification presented by Ruths et al. (Tidsskr Nor Laegeforen. 2007 Nov 29;127(23):3073-6). The different MRP categories will be reported as identified or not identified in the consultations.

    Time frame: At the first and second Medisinstart consultations and 12 months after initiation of the new medication for type 2 diabetes

  4. Patients' beliefs about their medicines

    Patients' beliefs about their medicines will be measured by a validated Norwegian translation of the Beliefs about Medicines Questionnaire (BMQ). The BMQ general comprises three subscales, Harm, Overuse and Benefit, and the total score of each subscale ranges from 4 to 20. The BMQ specific comprises two subscales, Concerns and Necessity, and the total score of each subscale ranges from 5 to 25. Higher scores indicate stronger beliefs in the concepts represented by the subscale.

    Time frame: At baseline and 6 months after initation of the new medication for type 2 diabetes

  5. Diabetes Self-Management

    Diabetes Self-Management will be measured by a validated Norwegian translation of the Diabetes Self-Management Questionnaire-Revised (DSMQ-R). The scores are summed and transformed into a 1-10 scale for each of the following activities: "eating behavior", "medication use", "glucose monitoring", "physical activity" and "interaction with treating physician/healthcare professional". In addition, a total score is calculated as an overall measure of the patient's diabetes self-management. Values in the upper part of the scale indicate good self-care.

    Time frame: 12 months after initiation of the new medication for type 2 diabetes

  6. Diabetes Treatment Satisfaction

    Diabetes Treatment Satisfaction will be measured by a validated Norwegian translation of the Diabetes Treatment Satisfaction Questionnaire (DTSQ). The scores range from 0 to 36 where higher scores indicate greater satisfaction with treatment.

    Time frame: At baseline and 6 and 12 months after initiation of the new medication for type 2 diabetes

07

Study locations

20 of 22 sites recruiting
  • Birkeland apotek
    Birkeland, Agder 4760, Norway
    Recruiting
  • Vitusapotek Gotaasgaarden Jessheim
    Jessheim, Akershus 2050, Norway
    Recruiting
  • Boots apotek Kløfta
    Kløfta, Akershus 2040, Norway
    Recruiting
  • Vitusapotek Nesodden
    Nesoddtangen, Akershus 1452, Norway
    Recruiting
  • Sykehusapoteket i Drammen
    Drammen, Buskerud 3004, Norway
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Apotek 1 Brandbu
    Brandbu, Innlandet 2760, Norway
    Recruiting
  • Vitusapotek Gjøvik
    Gjøvik, Innlandet 2806, Norway
    Recruiting
  • Apotek 1 Lena
    Lena, Innlandet 2850, Norway
    Recruiting
  • Sykehusapoteket Oslo, Ullevål
    Oslo, Oslo 0455, Norway
    Recruiting
  • Sykehusapoteket i Oslo, Aker
    Oslo, Oslo 0586, Norway
    Recruiting
  • Vitusapotek Røa
    Oslo, Oslo 0751, Norway
    Recruiting
  • Apotek 1 Veakrossen
    Kopervik, Rogaland 4276, Norway
    Recruiting
  • Vitusapotek Mariero
    Stavanger, Rogaland 4017, Norway
    Recruiting
  • Ryfylke apotek
    Stavanger, Rogaland 4150, Norway
    Recruiting
  • Vitusapotek Ulefoss
    Ulefoss, Telemark 3830, Norway
    Recruiting
  • Apotek 1 Andslimoen
    Bardufoss, Troms 9325, Norway
    Recruiting
  • Vitusapotek Åfjord
    Åfjord, Trøndelag 7170, Norway
    Recruiting
  • Sykehusapoteket i Trondheim
    Trondheim, Trøndelag 7030, Norway
    Recruiting
  • Apotek 1 Solsiden
    Trondheim, Trøndelag 7042, Norway
    Recruiting
  • Vitusapotek Paradis
    Bergen, Vestland 5232, Norway
    Recruiting
  • Vitusapotek Stryn
    Stryn, Vestland 6783, Norway
    Not yet recruiting
  • Boots apotek Linnea
    Øystese, Vestland 5610, Norway
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 36 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Feb 2026 → Feb 2027 and completion Feb 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Feb 22, 2024
StartActual
Feb 7, 2024
Primary completionEst.
Feb 2027was Feb 2026
CompletionEst.
Feb 2027was Feb 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
22 sites added, 19 sites removed
Show 22 added (22 Norway)
  • Birkeland apotek · Birkeland, Norway
  • Vitusapotek Gotaasgaarden Jessheim · Jessheim, Norway
  • Boots apotek Kløfta · Kløfta, Norway
  • Vitusapotek Nesodden · Nesoddtangen, Norway
  • Sykehusapoteket i Drammen · Drammen, Norway
  • Apotek 1 Brandbu · Brandbu, Norway
  • Vitusapotek Gjøvik · Gjøvik, Norway
  • Apotek 1 Lena · Lena, Norway
  • Sykehusapoteket Oslo, Ullevål · Oslo, Norway
  • Sykehusapoteket i Oslo, Aker · Oslo, Norway
  • Vitusapotek Røa · Oslo, Norway
  • Apotek 1 Veakrossen · Kopervik, Norway
  • Vitusapotek Mariero · Stavanger, Norway
  • Ryfylke apotek · Stavanger, Norway
  • Vitusapotek Ulefoss · Ulefoss, Norway
  • Apotek 1 Andslimoen · Bardufoss, Norway
  • Vitusapotek Åfjord · Åfjord, Norway
  • Sykehusapoteket i Trondheim · Trondheim, Norway
  • Apotek 1 Solsiden · Trondheim, Norway
  • Vitusapotek Paradis · Bergen, Norway
  • Vitusapotek Stryn · Stryn, Norway
  • Boots apotek Linnea · Øystese, Norway
Show 19 removed
  • Apotek 1 Andslimoen · Bardufoss, Norway
  • Apotek 1 Brandbu · Brandbu, Norway
  • Apotek 1 Brummundal · Brumunddal, Norway
  • Sykehusapoteket i Drammen · Drammen, Norway
  • Vitusapotek Gjøvik · Gjøvik, Norway
  • Vitusapotek Jessheim · Jessheim, Norway
  • Boots apotek Kløfta · Kløfta, Norway
  • Vitusapotek Leksvik · Leksvik, Norway
  • Apotek 1 Lena · Lena, Norway
  • Boots apotek Loddefjord · Loddefjord, Norway
  • Sykehusapoteket i Oslo, Aker · Oslo, Norway
  • Vitusapotek Røa · Oslo, Norway
  • Ryfylke apotek · Rennesøy, Norway
  • Vitusapotek Jekta · Tromsø, Norway
  • Sykehusapoteket i Trondheim · Trondheim, Norway
  • Vitusapotek Ulefoss · Ulefoss, Norway
  • Apotek 1 Veakrossen · Veavåg, Norway
  • Vitusapotek Åfjord · Åfjord, Norway
  • Boots apotek Linnea · Øystese, Norway
Oct 28, 2026
Primary completion
Feb 2026→Feb 2027
Oct 28, 2026
Study completion
Feb 2026→Feb 2027
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    22 sites added, 19 sites removed
    Show 22 added (22 Norway)
    • Birkeland apotek · Birkeland, Norway
    • Vitusapotek Gotaasgaarden Jessheim · Jessheim, Norway
    • Boots apotek Kløfta · Kløfta, Norway
    • Vitusapotek Nesodden · Nesoddtangen, Norway
    • Sykehusapoteket i Drammen · Drammen, Norway
    • Apotek 1 Brandbu · Brandbu, Norway
    • Vitusapotek Gjøvik · Gjøvik, Norway
    • Apotek 1 Lena · Lena, Norway
    • Sykehusapoteket Oslo, Ullevål · Oslo, Norway
    • Sykehusapoteket i Oslo, Aker · Oslo, Norway
    • Vitusapotek Røa · Oslo, Norway
    • Apotek 1 Veakrossen · Kopervik, Norway
    • Vitusapotek Mariero · Stavanger, Norway
    • Ryfylke apotek · Stavanger, Norway
    • Vitusapotek Ulefoss · Ulefoss, Norway
    • Apotek 1 Andslimoen · Bardufoss, Norway
    • Vitusapotek Åfjord · Åfjord, Norway
    • Sykehusapoteket i Trondheim · Trondheim, Norway
    • Apotek 1 Solsiden · Trondheim, Norway
    • Vitusapotek Paradis · Bergen, Norway
    • Vitusapotek Stryn · Stryn, Norway
    • Boots apotek Linnea · Øystese, Norway
    Show 19 removed
    • Apotek 1 Andslimoen · Bardufoss, Norway
    • Apotek 1 Brandbu · Brandbu, Norway
    • Apotek 1 Brummundal · Brumunddal, Norway
    • Sykehusapoteket i Drammen · Drammen, Norway
    • Vitusapotek Gjøvik · Gjøvik, Norway
    • Vitusapotek Jessheim · Jessheim, Norway
    • Boots apotek Kløfta · Kløfta, Norway
    • Vitusapotek Leksvik · Leksvik, Norway
    • Apotek 1 Lena · Lena, Norway
    • Boots apotek Loddefjord · Loddefjord, Norway
    • Sykehusapoteket i Oslo, Aker · Oslo, Norway
    • Vitusapotek Røa · Oslo, Norway
    • Ryfylke apotek · Rennesøy, Norway
    • Vitusapotek Jekta · Tromsø, Norway
    • Sykehusapoteket i Trondheim · Trondheim, Norway
    • Vitusapotek Ulefoss · Ulefoss, Norway
    • Apotek 1 Veakrossen · Veavåg, Norway
    • Vitusapotek Åfjord · Åfjord, Norway
    • Boots apotek Linnea · Øystese, Norway
    Primary completion Feb 2026→Feb 2027
    Study completion Feb 2026→Feb 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06273657
Lead sponsor
Apokus AS
Collaborators
Norwegian Pharmacy Association
Responsible party
Sponsor
First posted
Feb 22, 2024
Start date
Feb 7, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Sara Bremer, PhD
Contact
sara@apokus.no
21620200
Karine Wabø Ruud, PhD
Contact
karine@apokus.no
21620200
Sara Bremer, PhD
principal investigator · Head of Research and Development

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion